ceralasertib

News

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

News

A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.